Add to MyYahoo RSS

Biotech News

Biotech news continually updated from thousands of sources around the net.

1 hr ago | Lincoln Daily News

Valeant CEO 'disappointed' in Allergan poison pill: CNBC

T he chief executive officer of Valeant Pharmaceuticals, which made a $47 billion unsolicited offer for competitor Allergan Inc. on Tuesday, said during an interview on CNBC that he was "disappointed" with Allergan's so-called poison pill.


Related Topix: Allergan

5 hrs ago | MarketWatch

After Hours: Gilead shares climb; AT&T, Amgen shares fall

Gilead Sciences Inc., AT&T Inc. and Amgen Inc. were among the stocks actively trading Tuesday evening, with shares of Gilead climbing after handily beating Wall Street's quarterly earnings and revenue expectations and reporting a sales surge for its new hepatitis C treatment.


Related Topix: Medicine, Amgen, Healthcare Industry, Gilead Sciences, Cable & Satellite, Telecom, ATT, Startups, Financial Markets, Hepatitis, Health

Tue Apr 22, 2014

The Campbell Reporter

Biz Break: Gilead's new hepatitis C drug produces huge sales in debut quarter

Today: Gilead Sciences demolishes earnings expectations thanks to powerful sales of breakthrough hepatitis C drug Sovaldi.


Related Topix: Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals, Intuitive Surgical, Netflix, Telecom, Juniper Networks, Computers

Earnings give Wall Street sixth straight gain

US stocks rose on Tuesday as a host of solid earnings reports, along with strength in the healthcare sector, helped lift the S&P 500 and Nasdaq to their sixth straight advance.


Related Topix: Financial Markets, Allergan, Vicept Therapeutics, Valeant Pharmaceuticals International


Biotech Company Gilead Just Destroyed All Expectations For Sales Of Its New Hepatitis C Drug

Gilead Sciences is among the big biotech companies that have seen their shares whipsaw in the recent sell-off in biotech stocks .


Related Topix: Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals, Business News

Daily Journal

Pharma deals give stocks a lift

Amid a relative dearth of economic data and the lack of fresh news in Ukraine, investors are focusing on the latest batch of U.S. corporate earnings and the slew of developments in the pharmaceuticals industry.


Related Topix: Financial Markets, Medicine, GlaxoSmithKline, Healthcare Industry

Asbury Park Press

Exec at Bridgewater-based drug firm gets 16 months in inside-trade case

A former pharmaceutical executive has been sentenced to 15 months in prison for his role in an insider trading scheme.


Related Topix: Celgene, Medicine, Healthcare Industry

Bellingham Herald

Amgen misses 1Q views as higher costs cut profit

The company badly missed Wall Street's expectations for both earnings per share and revenue, sending down its shares.


Related Topix: Medicine, Amgen, Healthcare Industry, Osteoporosis, Health


Stocks up thanks to Netflix, big pharma

Thank you, Netflix. The company not only provides programming to fill your down time, it's also helping boost the stock market today.


Related Topix: Financial Markets, Motorcycles, Harley-Davidson Motorcycle, Allergan


Europe Markets: Drug stocks drive European markets higher

Drug makers took center stage in European trading Tuesday, with shares of AstraZeneca PLC climbing on news of a potential takeover bid, and GlaxoSmithKline PLC rising as it sells one of its units in a multibillion-dollar deal.


Related Topix: AstraZeneca, Medicine, AstraZeneca Group, Healthcare Industry, GlaxoSmithKline, Stanley, Pfizer

Burnley Citizen

GSK and Novartis agree tie-up deal

GlaxoSmithKline and Swiss rival Novartis are to create a consumer healthcare powerhouse as part of a string of deals in the pharmaceuticals sector today.


Related Topix: GlaxoSmithKline

The Huffington Post

Novartis Signs Multi-Billion Dollar Deals With GlaxoSmithKline, Lilly

Drug maker Novartis says it has signed several multibillion-dollar deals with GlaxoSmithKline and Lilly that will affect some 15,000 of its employees.


Related Topix: Novartis, GlaxoSmithKline, Medicine, Healthcare Industry

Mon Apr 21, 2014

Weyburn This Week

Valeant joins activist investor Ackman in bid for Botox maker Allergan

Shares in Valeant Pharmaceutical International Inc. soared in after-hours trading in New York on Monday after the Quebec-based company announced it had teamed with activist investor Bill Ackman in what looked to be a US$40-billion bid for Botox maker Allergan.


Related Topix: Allergan, Vicept Therapeutics, AckmanZiff Real Estate Group, Financial Services, Irvine, CA


Ackman, Valeant team up to bid for Allergan

Activist investor William Ackman teamed up with Canadian drugmaker Valeant Pharmaceuticals International Inc to make a joint run at buying wrinkle-treatment maker Allergan Inc, according to security filings on Monday.


Related Topix: Allergan

Lead Poisoning Nightmare In Nigeria May Be Easing

Gado Labbo holds her 5-year-old son, Yusuf, at a clinic in Dareta. In 2010, when Yusuf first entered the clinic, he had a blood lead level 30 times higher than the amount the Centers for Disease Control and Prevention considers dangerous.


Related Topix: Centers for Disease Control and Prevention, Medicine, Healthcare Industry


UPDATE 1-Pfizer agrees to $190 mln settlement over generic Neurontin

Pfizer Inc has agreed to pay $190 million to settle a class action lawsuit alleging the pharmaceutical company took steps to delay market entry of generic versions of its epilepsy drug Neurontin, according to court documents filed on Monday.


Related Topix: Neurontin, Gabapentin (generic), Medicine, Pfizer, Healthcare Industry


Aastrom Biosciences Acquires Sanofi's Cell Therapy and Regenerative Medicine Business

Aastrom Biosciences , a developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, reported that it has entered into an agreement to acquire Sanofi's Cell Therapy and Regenerative Medicine business for $6.5 million, with $4 million payable in cash at closing and $2.5 million payable ... (more)


Related Topix: Aastrom Biosciences

Lincoln Daily News

Supreme Court denies Teva stay in Copaxone patent fight

U.S. Supreme Court Chief Justice John Roberts on Friday denied a request by Teva Pharmaceutical Industries Ltd to stay a lower-court ruling in a patent case that favored the developers of generic versions of Teva's top-selling multiple sclerosis drug.


Related Topix: Teva Pharmaceutical Industries, US News, US Supreme Court, John G. Roberts


AstraZeneca cancer pipeline seen as draw for Pfizer

Pfizer may come back to bid for British drug company AstraZeneca after its reported 60 billion pound takeover approach was rejected, since a deal could make sense for the U.S. pharmaceuticals giant as it seeks to build up its cancer franchise.


Related Topix: Pfizer, Healthcare Industry

Ag Professional

GM food production increasing

The future in feeding the projected more than 9 billion world population by 2050 will require doubling the world's food production, according to the most accepted projections.


Related Topix: Agriculture, Science, Science / Technology, Potatoes, Life, Food, Vegetables


Biotech Jobs